<sentence id="0">Stimulation of the human immunodeficiency virus type 2 ( HIV-2 ) gene expression by the cytomegalovirus and HIV-2 transactivator gene .</sentence>
<sentence id="1">Human immunodeficiency virus ( HIV ) often causes latent infection .</sentence>
<sentence id="2">Transactivation by some DNA viruses has been implicated in inducing HIV-1 replication and pathogenesis .</sentence>
<sentence id="3">The transactivator ( IE-2 ) gene of the human cytomegalovirus ( CMV ) can enhance HIV-2 as well as HIV-1 gene expression in vitro .</sentence>
<sentence id="4">This inducer can act in concert with the HIV-2 tat gene and T-cell activation in enhancing gene expression in human CD4+ lymphocytes .</sentence>
<sentence id="5">While the HIV-2 and HIV-1 tat genes and T-cell activators apparently employ independent modes of action , the CMV transactivator in combination with the HIV-2 tat or T-cell activators <scope type="spec" id="0"> <cue type="spec" id="0">may</cue> employ a gene activation pathway with some common and some distinct components</scope> .</sentence>
<sentence id="6">Both HIV-2 and CMV transactivators enhance HIV-2 gene expression by transcriptional activation involving transcript initiation as well as elongation , with CMV transactivator affecting elongation more than the initiation .</sentence>
<sentence id="7"><scope type="spec" id="2"> A significant proportion of transcripts <cue type="spec" id="2">appear</cue> to terminate prematurely in the <scope type="neg" id="1"><cue type="neg" id="1">absence</cue> of transactivators</scope></scope> .</sentence>
<sentence id="8">Deletion mutation analysis of the HIV-2 long terminal repeat ( LTR ) <scope type="spec" id="3"> <cue type="spec" id="3">suggests</cue> that the element that responds to CMV transactivation in human CD4+ lymphocytes is <scope type="spec" id="4"> <cue type="spec" id="4">either</cue> a diffuse one or located downstream of the HIV-2 enhancer element</scope></scope> .</sentence>